ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for Pancreatic Cancer Patients at the University Hospital Antwerp (Belgium)
14 juin 2024 08h03 HE
|
Elmedix
A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer. Earlier this year, scientists from Columbia University in New...
Immuneering to Present at the Jefferies Global Healthcare Conference
29 mai 2024 16h05 HE
|
Immuneering Corporation
Immuneering to Present at the Jefferies Global Healthcare Conference
Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours
28 mai 2024 06h24 HE
|
Urteste S.A.
28 MAY 2024 PRESS RELEASE Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours Gdańsk, Poland – 28 MAY 2024, Urteste S.A. (Warsaw Stock...
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
24 mai 2024 08h45 HE
|
FN Media Group LLC
PALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the...
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
23 mai 2024 09h15 HE
|
Autonomix Medical, Inc.
Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass Lori Bisson, Chief Executive Officer...
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
07 mai 2024 16h05 HE
|
Immuneering Corporation
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Immuneering Recognizes Melanoma Awareness Month
06 mai 2024 16h30 HE
|
Immuneering Corporation
Immuneering Recognizes Melanoma Awareness Month
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
29 avr. 2024 08h55 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has taken an essential step forward in testing the...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
25 avr. 2024 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas
25 avr. 2024 05h00 HE
|
PEP-Therapy
Communiqué de presse PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patientsdans la phase Ib de l’essai clinique évaluant PEP-010dans les cancers de l’ovaire et du pancréas ...